How India Exports Crocin to the World

Paracetamol is approved in the United States under various brand names and generic formulations. According to the FDA's Orange Book, numerous Abbreviated New Drug Applications (ANDAs) have been approved for paracetamol products, indicating a well-established generic market. The most recent approval was granted in December 2025. As of March 2026, there are no active import alerts or significant regulatory actions against paracetamol products. Given the competitive landscape, Indian exporters aiming to enter the U.S. market must ensure compliance with FDA regulations, including Good Manufacturing Practices (GMP) and accurate labeling standards.

In the European Union, paracetamol is authorized for marketing through national procedures, as it is not subject to centralized approval by the European Medicines Agency (EMA). The Medicines and Healthcare products Regulatory Agency (MHRA) oversees paracetamol products in the United Kingdom. Both the EU and UK require adherence to stringent GMP standards, as outlined in EU Directive 2003/94/EC and the UK's Human Medicines Regulations 2012. Indian exporters must ensure their manufacturing facilities comply with these GMP requirements to access these markets.

Paracetamol is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The 24th edition of the list, published in September 2025, continues to feature paracetamol as a core medicine. This inclusion facilitates its acceptance and use in various international markets. Additionally, paracetamol is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality parameters across different regions.

In India, paracetamol is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for sale. The National Pharmaceutical Pricing Authority (NPPA) regulates its price to ensure affordability. As of January 2026, the ceiling price for paracetamol 500 mg tablets is set at INR 0.91 per tablet. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national policies and international obligations.

Paracetamol's primary patents have long expired, leading to a robust generic market globally. This lack of patent protection allows multiple manufacturers to produce and export paracetamol, resulting in competitive pricing and widespread availability.

In August 2025, the NPPA revised the ceiling price for paracetamol formulations, reducing it by 5% to enhance affordability. In October 2025, the Central Drugs Standard Control Organization (CDSCO) issued new guidelines for the export of pharmaceutical products, emphasizing stricter quality control measures. In December 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of paracetamol, which may influence procurement policies in various countries. In February 2026, the Indian Ministry of Commerce and Industry reported a 10% increase in paracetamol exports compared to the previous year, indicating growing international demand. In March 2026, the CDSCO conducted inspections of several paracetamol manufacturing facilities, resulting in the suspension of licenses for two manufacturers due to non-compliance with GMP standards.

These developments highlight the dynamic nature of the pharmaceutical industry and the importance of regulatory compliance for Indian exporters of paracetamol.

Crocin, a widely used analgesic and antipyretic, relies on paracetamol as its active pharmaceutical ingredient (API). India, a major producer of paracetamol APIs, sources a significant portion of its key starting materials (KSMs) from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting a critical dependency. This reliance exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or environmental regulations affecting Chinese manufacturing.

In response to these vulnerabilities, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Bulk Drugs, aiming to bolster domestic manufacturing of critical KSMs and APIs. As of March 2025, the scheme has led to an investment of ₹4,570 crore, surpassing the initial commitment of ₹3,938.5 crore over six years. This initiative has resulted in cumulative sales of ₹1,817 crore, including exports worth ₹455 crore, and has established domestic manufacturing capacity for 25 identified KSMs, drug intermediates, and APIs.

Our proprietary trade data indicates a high supplier concentration in Crocin exports from India. The top five exporters account for 80.8% of the total export value, with GOD GIFT LABORATORY PRIVATE LIMITED alone contributing 48.7%. Such concentration poses a significant single-source risk, as disruptions affecting these key suppliers could severely impact the supply chain.

The PLI Scheme for Bulk Drugs aims to mitigate these risks by promoting diversification and enhancing domestic production capabilities. By March 2025, the scheme had already led to import savings of ₹1,362 crore, underscoring its effectiveness in reducing dependency on a limited number of suppliers.

The global pharmaceutical supply chain is susceptible to geopolitical tensions and shipping disruptions. Critical maritime routes such as the Red Sea and the Strait of Hormuz are vulnerable to conflicts and blockades, potentially delaying shipments of APIs and finished products. Additionally, escalating U.S.-China trade tensions could lead to tariffs or export restrictions on essential raw materials, further straining the supply chain.

Regulatory bodies like the U.S. Food and Drug Administration (FDA) have previously issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP). For instance, in February 2025, the FDA flagged Global Calcium in India for cGMP violations, highlighting ongoing quality concerns and the risks associated with over-reliance on specific suppliers.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a limited number of sources.

• Strengthen Domestic Manufacturing: Leverage government initiatives like the PLI Scheme to enhance local production capabilities for critical APIs and KSMs.

• Monitor Geopolitical Developments: Establish a dedicated team to track international trade policies and geopolitical events that could impact the supply chain.

• Enhance Quality Assurance: Implement stringent quality control measures and conduct regular audits of suppliers to ensure compliance with cGMP standards.

• Develop Contingency Plans: Create comprehensive risk management strategies, including alternative shipping routes and emergency stockpiles, to mitigate potential disruptions.

RISK_LEVEL: MEDIUM